← Eichor
Study identifier: NCT06774365 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

CARdiac Imaging and BIomarkers in the Diagnosis of Antibody Mediated Rejection in Heart Transplantation

Condition: Heart Transplantation · Rejection Heart Transplant · HLA Antigens  ·  Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

PhaseN/A
Planned participants683
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this observational study is to systematically assess the presence and distribution of CMR-defined inflammation and fibrosis in clinically stable HT recipients with DSA detected during active screening for AMR surveillance. The main outcome is to study the prevalence of fibrosis, edema and of altered T1 mapping values in patients with DSA and the prevalence of patients with DSA among all the enrolled patients

This description comes directly from the study's public registry record.

Talk to the study team

Luciano Potena, MD  ·  0512143725  ·  scompenso.trapiantocuore@aosp.bo.it

Always discuss trial participation with your own doctor first.

Locations (4)

Azienda Ospedaliera Universitaria Consorziale Policlinico di BariBari, Bari, ItalyNot Yet Recruiting
IRCCS Azienda Ospedaliero-Universitaria di BolognaBologna, Bologna, ItalyRecruiting
ASST Grande Ospedale Metropolitano NiguardaMilan, Milano, ItalyRecruiting
Azienda Ospedaliera dei ColliNaples, Napoli, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06774365